STOCK TITAN

Aquestive Therapeutics Inc - AQST STOCK NEWS

Welcome to our dedicated news page for Aquestive Therapeutics (Ticker: AQST), a resource for investors and traders seeking the latest updates and insights on Aquestive Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aquestive Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aquestive Therapeutics's position in the market.

Rhea-AI Summary
Aquestive Therapeutics, Inc. successfully closed a public offering of 16,666,667 shares of common stock at $4.50 per share, raising approximately $75.0 million. Leerink Partners and Piper Sandler were the joint bookrunning managers for the offering. The Company aims to advance medicines using innovative science and delivery technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.57%
Tags
offering
-
Rhea-AI Summary
Aquestive Therapeutics, Inc. (NASDAQ: AQST) announced a public offering of 16,666,667 shares of common stock at $4.50 per share, aiming to raise approximately $75.0 million for product pipeline development and commercialization. The offering includes Anaphylm™ for severe allergic reactions and Libervant™ for seizure clusters.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.64%
Tags
offering
-
Rhea-AI Summary
Aquestive Therapeutics, Inc. (AQST) announces a public offering of common stock to raise funds for product pipeline development and commercialization. The offering includes an option for additional shares, managed by Leerink Partners and Piper Sandler. The proceeds will support the advancement of Anaphylm™ and Libervant™ products, among others.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.64%
Tags
offering
Rhea-AI Summary
Aquestive Therapeutics, Inc. releases positive Phase 3 clinical data for Anaphylm, an orally administered epinephrine product for severe allergic reactions. The data shows Anaphylm's rapid absorption and sustained levels comparable to autoinjectors. The FDA feedback is positive, reaffirming the company's goal of filing NDA by the end of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16%
Tags
clinical trial
-
Rhea-AI Summary
Aquestive Therapeutics reports full year 2023 revenue of $50.6 million with a non-GAAP adjusted EBITDA loss of $11.6 million. The company reaffirms the expected release of topline pivotal clinical data for Anaphylm in March 2024 and the anticipated FDA decision on Libervant application in April 2024. Aquestive provides full year 2024 financial guidance and hosts an investment community conference call on March 6, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.05%
Tags
earnings
-
Rhea-AI Summary
Aquestive Therapeutics, Inc. (NASDAQ: AQST) will report Q4 2023 results on March 5, 2024, with a conference call for investors on March 6, 2024. A live webcast and replay will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.28%
Tags
conferences earnings
Rhea-AI Summary
Aquestive Therapeutics (AQST) announces positive clinical trial data for Anaphylm™, an orally administered epinephrine product, showing comparable results to autoinjectors. The Phase 3 pivotal study is ongoing, with topline data expected in Q1 2024. The data will be presented at the AAAAI 2024 annual meeting, highlighting the potential of Anaphylm as a needle-free alternative for treating severe allergic reactions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
conferences
-
Rhea-AI Summary
Aquestive Therapeutics, Inc. (NASDAQ: AQST) will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13th, holding a fireside chat and investor meetings. A webcast and replay will be available on the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.25%
Tags
conferences
-
Rhea-AI Summary
Aquestive Therapeutics, Inc. (NASDAQ: AQST) has initiated its initial Phase 3 pivotal Pharmacokinetic (PK) clinical study of Anaphylm™ (epinephrine) Sublingual Film, the Company’s orally administered epinephrine prodrug product candidate for the treatment of severe life-threatening allergic reactions, including anaphylaxis. The study aims to compare the PK and pharmacodynamics (PD) of Anaphylm versus existing epinephrine injection and autoinjector products. The topline data is expected in the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.24%
Tags
clinical trial
Rhea-AI Summary
Aquestive Therapeutics, Inc. (NASDAQ: AQST) announced positive data from pharmacokinetic (PK) and pharmacodynamic (PD) pre-clinical and clinical studies of Anaphylm™ (epinephrine) Sublingual Film to be presented at the ACAAI annual meeting. The results show promising potential for the treatment of acute allergic reactions, pending FDA approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
conferences
Aquestive Therapeutics Inc

Nasdaq:AQST

AQST Rankings

AQST Stock Data

368.87M
69.54M
5.03%
27.93%
2.64%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
Warren

About AQST

aquestive therapeutics is a specialty pharmaceutical company that advances and commercializes medicines to solve critical healthcare problems and meaningfully improve people’s lives. our team asks questions and identifies issues others have not, and builds solutions that empower patients and their caregivers with better ways to manage complex diseases. our initial focus, supported by our current approved products and late stage pipeline, is to address immediate cns challenges.